APPENDIX 1: 2020-21 Publicly Funded Influenza Vaccines

	FluLaval® Tetra (GSK) QIV split virion	**FLUZONE® Quadrivalent** (SP) QIV split virion	**FLUZONE® High Dose** (SP) TIV split virion
Population	Everyone ≥ 6 months	Everyone ≥ 6 months	LTC and PCH residents ≥ 65 years
Dose	0.5 mL IM	0.5 mL IM	0.5 mL IM
Components	Latex and antibiotic free and contains both influenza A strains and B viral strains, sodium chloride, potassium chloride, disodium hydrogen phosphate heptahydrate, potassium dihydrogen phosphate, α-tocopheryl hydrogen succinate, and polysorbate 80, and may contain traces of egg proteins (ovalbumin), sodium deoxycholate, ethanol, formaldehyde and sucrose.	Latex, antibiotic and gelatin free and contains all surface antigens of this year's influenza A and B viral strains, formaldehyde, sodium phosphate-buffered, isotonic sodium chloride solution, and Triton® X-100, and may contain traces of egg protein and sucrose.	Latex, antibiotic, thimerosal and gelatin free and contains all surface antigens of this year's influenza A strains and one B viral strain, formaldehyde, sodium phosphate-buffered, isotonic sodium chloride solution, and Triton® X-100, and may contain traces of egg protein.
Preservative	• Thimerosal in multidose vials.	• Thimerosal in multidose vials.	• No preservatives
Normal and Expected Reactions Mild to moderate reactions generally last 1-4 days.	• Pain (60%), redness (2%), and swelling (3%)at the injection site. • Headache (22%), fever (2%), tiredness (22%), muscle aches (26%), and shivering (9%). • Loss of appetite (9%)	• The most common reactions occurring after vaccine administration are injection site pain (11%-57%), erythema (7%-30%) and edema (6%-21%). • The most common systemic reactions observed after vaccine administration are asthenia (2%-18%), headache (2%-10%) and myalgia (2%-9%).	• The most common reactions occurring after vaccine administration are injection site pain (36%), erythema (15%) and edema (9%). • The most common systemic reactions observed after vaccine administration includes myalgia (21%), malaise (18%) and (2%-18%), headache (17%).
Presentation	• 5 mL multidose vial containing 10 doses of 0.5 mL	• 5 mL multidose vial containing 10 doses of 0.5 mL • 0.5 mL prefilled syringes (thimerosal free)	• 0.5 mL prefilled syringes (thimerosal free)
Contra-indications	• Persons with a history of a severe allergic or anaphylactic reaction to a previous flu vaccine dose or any component of a flu vaccine should discuss their situation with a public health nurse (PHN) or their physician. • Persons who developed GBS within six weeks of a previous flu vaccine.		
Instructions for Administration	• Do not administer vaccine from a vial that has been opened for ≥28 days or has expired. • **To get 10 doses out of a vial, GSK recommends that each 0.5 mL dose is withdrawn into a 1 mL syringe equipped with a needle gauge not larger than a 23G**.	• Vaccine may be administered from a MDV that has been opened up to the expiry date indicated on the vial.	• Nothing specific for this vaccine.
Special Instructions –	• Gently shake pre-filled syringes or vials before administration • Date vials when opened. • Store at 2°C-8°C. • Do not freeze or use if vaccine has been frozen. • Protect from light. • Pre-drawing is not recommended. • The Ministry recommends that vaccines be administered directly from the fridge or cooler and not warmed to room temperature prior to administration.		